PUMA BIOTECHNOLOGY, INC. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
PUMA Biotechnology reported Q2 2026 total revenue of $56.5M ($53.6M product, $2.9M royalty) versus $52.4M in Q2 2025, and net income of $8.2M ($0.16/share) versus $5.9M ($0.12/share). The company raised full-year 2026 guidance from $222–$229M to $224–$231M total revenue and from $16–$19M to $17–$20M net income, citing increased NERLYNX demand. Cash position is $93.9M as of June 30, 2026; debt was eliminated in May 2026. R&D expenses increased $9.4M year-to-date (primarily $7.4M for alisertib clinical trials). No material counterparty transactions or specific deal announcements.
Why this rating
Modest revenue growth (+8% YoY Q2) and guidance raise are modest positives; however, H1 net income down 50% YoY due to doubled R&D spend. Company profitable but operating at ~$145M market cap; event is material but not transformational.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.